Biotech M&A – 2018 Deals

Biotech M&A – 2018 Deals

Biotech M&A With a Strong Start in 2018: More Deals to Follow?

DateAcquirer co.Acquirer tickerAcquired co.Acquired tickerDeal valuePrice/ShareCVR (if any)Notes
01/05/2018TakedaTKPYYTiGenix G9U.BR$626M1.78 euroBelgian Co.
01/07/2018CelgenCELGImpact BiomedicinesPrivate$1.1B$7B milestones
01/22/2018SanofiSNYBioverativBIVV$11.6B$105Belgian Co.
01/22/2018CelgenCELGJunoJUNO$9B$87
1/29/2018SanofiSNYAblynx NVABLX$4.8B$55.61Outbid Novo Nordisk
01/29/2018Varian Medical SystemsVARSirtexSRX.AX$1.28B$28Australian Co.
02/13/2018Astellas PharmaALPMYUniversal CellsPrivate$102.5Mmilestones to acquire 100% ownership
02/21/2018MerckMRKViralyticsVLA.AX$394MAu$1.75Australian Co.
04/09/2018NovartisNVSAveXisAVXS$8.7B$218SMA GeneTherapy
04/11/2018AlexionALXNWilson Therapeutics WTX.ST$855M$27.93Stockholm, Sweden,
04/26/2018Endo InternationalENDPSomerset TherapeuticsPrivate$190Msterile injectable and ophthalmic drugs
04/30/2018United TherapeuticsUTHRSteadyMed Ltd.STDY$216M$4.46additional $2.63/ share upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.
05/10/2018Eli LillyLLYARMO BioSciencesARMO$1.6B$50
10/11/2018Gurnet Point CapitalPrivate Co.Corium InternationalCORI $504M$12.5CVR of $0.50 per share
10/18/2018Novartis NVSEndocyteECYT$2.1B$24
12/03/2018GlaxoSmithKlineGSKTesaroTSRO$5.1B$75

Recent Press

Slider

Log In

JoinLost Password?